Skip to main content
CLVT logo

CLVT · Clarivate PLC

Track CLVT — free
$2.17 +0.01 (+0.23%)
Market Cap
$1.38B
Shares
639.90M
Volume · Nov 19 683.45K Avg daily vol (3M) 4.13M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.16 Open$2.15 Day$2.07–2.19 52W close$1.45–3.76 Avg vol 30d4.0M Short int48.4M · 7.6% of shares · 13.8d Short vol35% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 23, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Investor event
2027 free cash flow seen rising 10% to 15%

Clarivate expects free cash flow to grow about 10% to 15% in 2027 from its exit level, helped by much lower one-time transactional costs, a full-year benefit of recent debt reduction and capital expenditure under 10% of revenue. The company completed a tender offer and debt repurchase totaling $533 million and expects leverage of about three and a half times for 2027.

6 source passages
we expect for 2027 to be able to grow free cash flow from where we exit this year by about 10% to 15% in this coming year. there was a higher amount of one-timer transactional costs that were a drag on free cash flow. That's going to go down significantly in this coming year. We'll get the full-year benefit of that in 2027. We'll see that get under 10% in 2027. ended up upsizing it by another $33 million to go out with a total $533 million debt repurchase. we expect to end the year about three and a half times leverage. Open the document at this passage
Nov 18
Investor event
Expects 2027 free cash flow to grow 10% to 15%

Clarivate expects free cash flow to grow 10% to 15% in 2027 from where it exits this year, helped by lower one-time transaction costs, lower cash interest and CapEx falling under 10% of revenue. A tender offer ended with a total $533 million debt repurchase, and the company expects about three and a half times leverage by the end of 2027.

4 source passages
we expect for 2027 to be able to grow free cash flow from where we exit this year by about 10% to 15% in this coming year. We'll see that get under 10% in 2027. ended up upsizing it by another $33 million to go out with a total $533 million debt repurchase. We gave an indication that for 2027, we expect to end the year about three and a half times leverage. Open the document at this passage
Nov 12
Current report 8-K
Cash tenders accept $533,000,000 of notes

Clarivate Science Holdings Corporation accepted $533,000,000 total aggregate principal amount of notes, with the 2028 Notes and 2029 Notes accepted at proration factors of approximately 67.9% and 45.5%, respectively.

Other events
Source passage
will accept for purchase $533,000,000 total aggregate principal amount of the Notes, with the tendered 2028 Notes and 2029 Notes accepted at a proration factor of approximately 67.9% and 45.5%, respectively. Open the document at this passage
Nov 10
Current report 8-K
Debt tender offers priced at $979.08 and $928.75

Clarivate Plc announced pricing for tender offers of 3.875% Senior Secured Notes due 2028 and 4.875% Senior Notes due 2029, at $979.08 and $928.75 per $1,000 principal amount, with series caps of $415,000,000 and $118,000,000 after 2% increases.

Other events
6 source passages
Clarivate Plc (NYSE: CLVT) The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the “2029 Notes") Additionally, the Company has exercised its right to increase the aggregate principal amount of 2028 Notes and 2029 Notes accepted for purchase by 2% of the outstanding aggregate principal amount of each Series of Notes. 3.875% Senior Secured Notes due 2028 | Clarivate Science Holdings Corporation | 144A: 18064P AC3 / US18064PAC32 Reg S: U1800Q AC3 / USU1800QAC34 | $750,000,000 | $415,000,000 | 4.125% UST due June 30, 2028 | 4.725% | FIT 4 | +50 | $979.08 4.875% Senior Notes due 2029 | Clarivate Science Holdings Corporation | 144A: 18064P AD1 / US18064PAD15 Reg S: U1800Q AD1 / USU1800QAD17 | $900,000,000 | $118,000,000 | - | - | - | - | $928.75 Represents the applicable total consideration for the 2028 Notes (the "2028 Notes Total Consideration) and the 2029 Notes (the "2029 Notes Total Consideration") payable per each $1,000 principal amount of the applicable Series of Notes validly tendered and accepted for purchase in the applicable Offer. Open the document at this passage
Nov 4
Current report 8-K
Debt tender offers capped at $500,000,000

Clarivate announced cash tender offers for certain debt securities, capped at $500,000,000 aggregate and scheduled to expire on November 10, 2026 unless extended.

Other events
3 source passages
On November 4, 2026, Clarivate Plc issued a press release announcing the launch of cash tender offers by its wholly-owned subsidiary, Clarivate Science Holdings Corporation, for certain of its debt securities. The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the “2028 Notes”) and its 4.875% Senior Notes due 2029 (the “2029 Notes” and, together with the 2028 Notes, the “Notes” and, each, a “Series of Notes”) for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a “Series Cap”) set forth in the Offer to Purchase. The Offers are scheduled to expire on the Expiration Date, which is 5:00 p.m., New York City time, on November 10, 2026, unless extended or earlier terminated by the Company with respect to any Offer. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.36B
Trailing 12 months
Net income (TTM)
−$386.50M
Trailing 12 months
Revenue growth YoY
-9.2%
Year over year
Operating margin
-3.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
23.3%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$3.88B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-4.3%
Year over year · fewer shares
Price change (1Y)
-34.7%
Trailing year
Short interest
7.6%
Latest settlement · 13.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Clarivate reaffirmed its full-year 2026 outlook, expecting ~200 bps adjusted EBITDA margin expansion and ~$900M of debt paydown, while Q2 net loss widened to $268.6M due to a $221.7M non-cash goodwill impairment linked to the pending Life Sciences & Healthcare divestiture.

Bullish
  • + Full-year 2026 outlook reaffirmed with adjusted EBITDA margin guided to expand ~200 bps
  • + Free cash flow guided at low end of $365M–$435M range with plan to retire ~$900M of debt using FCF and LS&H divestiture proceeds
  • + H1 adjusted EBITDA margin expanded 90 bps to 41.6% on recurring growth and cost discipline
  • + Total debt reduced by $218.4M in H1 via opportunistic repurchases at a discount to par
  • + Organic ACV grew 1.5% with H1 subscription organic growth up 60 bps YoY to 1.2%
Bearish
  • − Q2 GAAP net loss widened to $268.6M ($0.42/share) on a $221.7M non-cash goodwill impairment tied to the LS&H divestiture
  • − Q2 Adjusted EBITDA declined 5.5% to $247.2M, with H1 free cash flow down 23.5% to $122.9M
  • − Full-year 2026 free cash flow guided to be flat YoY at low end of range due to ~$70M of one-time LS&H transaction costs
  • − H1 operating cash flow declined 18.8% to $233.4M driven by lower EBITDA and higher working capital use

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −1%
below
Price vs 50-day avg +16%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 31%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +23%
trailing
6-month return −15%
trailing
YTD return −35%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.57% of shares out · ▲ +3.5% MoM · 13.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
222 holders — mid 3-yr range
Squeeze score 76
high risk · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
EPS growth +69%
Y/Y
Free cash flow $365.3M
Buyback $350.5M
remaining
Balance sheet $4.1B
net debt
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −61%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 5
Latest guidance · from the 8-K filed Nov 3, 2026
Full Year 2026
Revenues Lowered $1.97B – $1.99B
Apr 29, 2026 $2.3B – $2.42B changed to Nov 3, 2026 $1.97B – $1.99B
prior FY $2.46B midpoint −19.6% Y/Y
Adjusted EBITDA Non-GAAP Lowered $865M – $885M
Jul 29, 2026 $980M – $1.04B changed to Nov 3, 2026 $865M – $885M
Adjusted EBITDA Margin Non-GAAP Raised 43% – 45%
Jul 29, 2026 42% – 43.5% changed to Nov 3, 2026 43% – 45%
Adjusted Diluted EPS Non-GAAP Maintained $0.73 – $0.77
Jul 29, 2026 $0.70 – $0.80 changed to Nov 3, 2026 $0.73 – $0.77
Free Cash Flow Non-GAAP Lowered $320M – $340M
Jul 29, 2026 $365M – $435M changed to Nov 3, 2026 $320M – $340M
Q4 2026
Revenues $490M – $510M
prior qtr $481.6M midpoint +3.8% QoQ
Adjusted EBITDA Non-GAAP $215M – $235M
Adjusted EBITDA Margin Non-GAAP 44% – 46%
Free Cash Flow Non-GAAP $85M – $105M
Adjusted Diluted EPS Non-GAAP $0.14 – $0.18
FY 2026
Adj. EBITDA Margin Non-GAAP 43% – 45%
Previous outlook earlier release · from the 8-K filed Apr 29, 2026

Still-open targets the latest release did not restate under the same label.

Organic ACV · Full Year 2026 Outlook 2% – 3%
Recurring Organic Revenue Growth · Full Year 2026 Outlook 0.75% – 2.25%
Net income (loss) per share · Year Ending December 31, 2026 $-0.29 – $-0.19
Guided vs delivered · last 5 settled
Revenues Full Year 2025
guided $2.42B – $2.45B
$2.46B Beat +0.8%
Revenues 2024 Outlook
guided $2.57B – $2.67B
$2.56B Miss −2.4%
Revenues 2023 Outlook
guided $2.6B – $2.67B
$2.63B In line
Revenues Updated 2022 Outlook
guided $2.6B – $2.66B
$2.66B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−1% Neutral
Price vs 50-day avg
+16% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
31% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +36 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.57% of shares out · ▲ +3.5% MoM · 13.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
222 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 31% Range high $4
vs 200-day avg -1% vs 50-day avg +16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
A&G Adjusted EBITDA non-GAAP $136.5M the three months ended June 30, 2026 filing —
Adjusted diluted EPS non-GAAP $0.38 Six Months Ended June 30, 2026 —
Adjusted EBITDA margin non-GAAP 41.6% Six Months Ended June 30, 2026 —
Adjusted net income non-GAAP $242.4M first six months of 2026 —
Adjusted net income and Adjusted diluted EPS non-GAAP 242.4M Six Months Ended June 30, 2026 —
Adjusted weighted average ordinary shares, diluted non-GAAP 645M Six Months Ended June 30, 2026 —
Free cash flow non-GAAP $122.9M first six months of 2026 —
H1 debt reduction $218M H1 2026 —
IP Adjusted EBITDA non-GAAP $86.4M the three months ended June 30, 2026 filing —
LS&H Adjusted EBITDA non-GAAP $24.3M the three months ended June 30, 2026 filing —
Organic ACV and subs revenue growth 2% Q2 2026 —
Organic ACV growth 1.5% second quarter of 2026 —
Organic recurring revenues 0.7% first six months of 2026 —
Organic revenues decrease 0.4% first six months of 2026 —
Organic subscription growth 0.7% second quarter of 2026 —
Organic transactional revenues decrease 15.7% second quarter of 2026 —
Recurring Organic Growth 0.7% Q2 2026 —
Recurring revenues 0.5% second quarter of 2026 —
Subs Organic Growth 1.2% H1 2026 —
total ACV 3.1% June 30, 2026 —
Total Reportable Segments Adjusted EBITDA non-GAAP $247.2M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Information Technology Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLVT
Clarivate PLC
this stock
$1.38B -35.3% +0.6% — 7.6%
IBM
International Business Machines Corp
$214.50B -22.8% +7.6% 19.3 1.9%
ACN
Accenture plc
$152.20B -15.2% +6.5% 16.8 3.2%
INFY
Infosys Ltd
$47.43B -33.9% — — 2.1%
CTSH
Cognizant Technology Solutions Corp
$25.91B -30.2% +7.0% 10.6 5.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
222
% held
86.4%
Net QoQ
-29.9M sh
Top holder
Leonard Green & Partners,…
Held Float
View
Held by Funds
Fund positions
63
View
Short & Settlement
Short Interest Rising
Shares short
48.4M
Days to cover
13.8d
Change
+1.6M sh
View
Short Volume
Short vol %
35%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
397.5K
Value
$735.4K
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
45.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 12, 2023
View
Financials
Financials
Revenue (FY)
$2.5B
Net income (FY)
$-201.1M
EPS diluted
$-0.30
View
Buybacks
Authorized
$500.0M
Remaining
$350.5M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
29

Clarivate expects free cash flow to grow about 10% to 15% in 2027 from its exit level, helped by much lower one-time transactional costs, a full-year benefit of recent debt reduction and capital expenditure under 10% of revenue. The company completed a tender offer and debt repurchase totaling $533 million and expects leverage of about three and a half times for 2027.

View
Proposed Sales
Value
$542.3K
Shares
254.6K
Filed
Nov 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Clarivate Reveals Highly Cited Re…
Published
Nov 18, 2026
View

Performance

5D 20D 120D MTD YTD
CLVT -6.9% +22.7% -14.6% +30.9% -35.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -3.0% +28.3% -11.2% +34.3% -42.4%

Capital returns

Buyback program · as of Sep 30, 2025
Authorized
$500.00M
Spent (derived)
$149.50M
Remaining
$350.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1764046 CUSIP G21810109 13F (30d) 227 filings 208 filers Visit website Investor relations